Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Liso-cel vs tisa-cel in third-line DLBCL treatment

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, outlines the results of a retrospective study comparing lisocabtagene maraleucel (liso-cel) and tisagenlecleucel (tisa-cel) in patients with diffuse large B-cell lymphoma (DLBCL) in the third-line setting. Whilst both CAR-T therapies had a favorable safety profile, liso-cel appeared to be more effective. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Karyopharma, DSB; Honoraria from Karyopharma, Merck; Research funding from Merck